Our news

Our news

Bellco announces the acquisition of HBiofluids

The Mirandola-based Bellco, leader in systems for dialysis and extracorporeal blood purification, has made an important new acquisition to consolidate its market position.

Bellco, among the market leaders in systems for dialysis and extracorporeal blood purification, has consolidated its market position through the acquisition of HBiofluids.

HBiofluids was formed as a pharmaceutical company in 2002 by Argentinean businessman Juan Boris Scalesciani and produces fluids for dialysis, haemofiltration and intravenous therapy.

Ever since its formation, HBiofluids has operated as a full contract manufacturer covering the entire medical fluid supply chain, from production to marketing. The company’s technologically advanced production plants are located in the Valtellina area of northern Italy, where the water possesses ideal characteristics for medical use. HBiofluids is certified for its application of GMP (Good Manufacturing Practice), the strictest standard governing the production of pharmaceutical products.

HBiofluids currently supplies some of the leading enterprises in the field of extracorporeal blood purification for chronic and intensive care patients, and for home dialysis and peritoneal dialysis too. Acquisition by Bellco will allow HBiofluids to maintain and consolidate its existing business, and, more important, will enable Bellco to integrate its upstream activities in the high-added-value business of medical fluid production.

“The acquisition of HBiofluids is an important strategic decision from our side” declared Antonio Leone, Chairman of Bellco. “I am delighted that we have been able to leverage on such an important opportunity to support Bellco’s growth plans. I am also particularly pleased that the Scalesciani family has decided to maintain a 20% shareholding in HBiofluids.”

Carlo Medici, Bellco’s CEO added “Our acquisition of HBiofluids will enable Bellco to move ever closer towards the objective of delivering a complete service to public and private dialysis centres. It will also allow us to grow significantly in the field of intensive care, where intravenous fluids play an integral and fundamental role in patient therapy. This is what promoting Italian excellence in the high-tech biomedical sector means for us”.

Privacy Statement

This website is operated by Charme Capital Partners SGR S.p.A. for Charme Capital Partners Limited and its affiliates (“we” or “us”). This privacy statement outlines how we use any information you may provide to us when you visit our website, and includes details of our use of cookies. If you wish to contact us in relation to our use, storage or processing of your personal data, please contact us.

If you contact us via the ‘Get In Touch’ form on our website we will hold your name and email address (as well as any other personal information you may send us, such as your phone number), which we will use to respond to your enquiry. We may also use this information to send you other business and marketing communications. If you do not wish to receive such communications you should opt out by contacting us at the email address above. As part of our processing activities we may transfer your personal information outside the EEA. While some countries outside the EEA do not offer the same level of protection for personal data as countries within the EEA, we will take all reasonable steps to ensure that your personal data is processed securely and with an adequate level of protection.

Cookies

We use cookies as set out below. Cookies are text files containing small amounts of information which are downloaded to your device when you visit a website and sent back to the originating web domain on your subsequent visits to that domain. Most web pages contain elements from multiple web domains. If you do not agree to our use of these cookies please disable them by following the instructions for your browser set out here or use the cookies’ own automated disabling tools.

We make use of analytic cookies to analyse how our visitors use our website and to monitor website performance. This allows us to provide a high quality experience by customising our offering and quickly identifying and fixing any issues that arise. Our website currently uses the following performance cookies:

Cookie name Source Purpose Further information
_utma,
_utmb,
_utmc,
_utmz
Google Analytics These cookies are used to collect information about how visitors use our website. These cookies collect information in an anonymous form, including the number of visitors to the portal, where visitors have come to the site from and the pages they visit. Persistent (except _utmc, which is a session cookie). Google Analytics provides an opt-out facility at: https://tools.google.com/dlpage/gaoptout Further information about Google’s privacy measures can be found at: https://support.google.com/analytics/ answer/6004245

We may also use your IP address and browser type to help diagnose problems with our server, to administer our products and to improve the functionality of our website. An IP address is a numeric code that identifies a user’s computer on the internet. It might also be used to gather broad demographic information. We do not use IP addresses to derive the identity of the person using the IP address.

We may make changes to this privacy statement from time to time. We therefore encourage you to review it periodically to stay informed of how we are using personal information.